Designing the epitope flanking regions for optimal generation of CTL epitopes

Vaccine

Volumn 32, Issue 28, 2014, Pages 3509-3516

  Steers, Nicholas J ^a,b   Currier, Jeffrey R ^a,b   Jobe, Ousman ^a,b   Tovanabutra, Sodsai ^a,b   Ratto Kim, Silvia ^a,b   Marovich, Mary A ^a,c   Kim, Jerome H ^a   Michael, Nelson L ^a   Alving, Carl R ^a   Rao, Mangala ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CTL epitope; Gag p24; HIV 1; Immunogen design; Proteasome; Synthetic flanking region

Indexed keywords

EPITOPE; GAMMA INTERFERON; PROTEASOME; VIRUS PROTEIN; GAG PROTEIN; P24 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; PEPTIDE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA FLANKING REGION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINIA; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HIV CORE PROTEIN P24; HUMANS; INTERFERON-GAMMA; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84901433757     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.039     Document Type: Article

References (48)

1. Kloetzel P.M., Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004, 16:76-81.
2. Loureiro J., Ploegh H.L. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv Immunol 2006, 92:225-305.
3. Saric T., Graef C.I., Goldberg A.L. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 2004, 279:46723-46732.
4. Cascio P., Hilton C., Kisselev A.F., Rock K.L., Goldberg A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 2001, 20:2357-2366.
5. van Endert P. Post-proteasomal and proteasome-independent generation of MHC class I ligands. Cell Mol Life Sci 2011, 68:1553-1567.
6. Reits E., Neijssen J., Herberts C., Benckhuijsen W., Janssen L., Drijfhout J.W., et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 2004, 20:495-506.
7. Kessler J.H., Khan S., Seifert U., Le Gall S., Chow K.M., Paschen A., et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol 2011, 12:45-53.
8. Kim E., Kwak H., Ahn K. Cytosolic aminopeptidases influence MHC class I-mediated antigen presentation in an allele-dependent manner. J Immunol 2009, 183:7379-7387.
9. Bhutani N., Venkatraman P., Goldberg A.L. Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. EMBO J 2007, 26:1385-1396.
10. Hearn A., York I.A., Rock K.L. The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol 2009, 183:5526-5536.
11. Shastri N., Cardinaud S., Schwab S.R., Serwold T., Kunisawa J. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 2005, 207:31-41.
12. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
13. Steers N.J., Currier J.R., Kijak G.H., di Targiani R.C., Saxena A., Marovich M.A., et al. Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire. J Virol 2011, 85:1541-1553.
14. Kloetzel P.M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179-187.
15. Nil A., Firat E., Sobek V., Eichmann K., Niedermann G. Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur J Immunol 2004, 34:2681-2689.
16. Steers N.J., Alving C.R., Rao M. Modulation of immunoproteasome subunits by liposomal lipid A. Vaccine 2008, 26:2849-2859.
17. Dahlmann B., Ruppert T., Kuehn L., Merforth S., Kloetzel P.M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 2000, 303:643-653.
18. Boes B., Hengel H., Ruppert T., Multhaup G., Koszinowski U.H., Kloetzel P.M. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 1994, 179:901-909.
19. Chapiro J., Claverol S., Piette F., Ma W., Stroobant V., Guillaume B., et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol 2006, 176:1053-1061.
20. Toes R.E., Nussbaum A.K., Degermann S., Schirle M., Emmerich N.P., Kraft M., et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001, 194:1-12.
21. Tenzer S., Wee E., Burgevin A., Stewart-Jones G., Friis L., Lamberth K., et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009, 10:636-646.
22. Kuckelkorn U., Ruppert T., Strehl B., Jungblut P.R., Zimny-Arndt U., Lamer S., et al. Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J Exp Med 2002, 195:983-990.
23. Eisenlohr L.C., Yewdell J.W., Bennink J.R. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med 1992, 175:481-487.
24. Milicic A., Edwards C.T., Hue S., Fox J., Brown H., Pillay T., et al. Sexual transmission of single human immunodeficiency virus type 1 virions encoding highly polymorphic multisite cytotoxic T-lymphocyte escape variants. J Virol 2005, 79:13953-13962.
25. Mo A.X., van Lelyveld S.F., Craiu A., Rock K.L. Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J Immunol 2000, 164:4003-4010.
26. Yellen-Shaw A.J., Wherry E.J., Dubois G.C., Eisenlohr L.C. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J Immunol 1997, 158:3227-3234.
27. Milicic A., Price D.A., Zimbwa P., Booth B.L., Brown H.L., Easterbrook P.J., et al. CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol 2005, 175:4618-4626.
28. Le Gall S., Stamegna P., Walker B.D. Portable flanking sequences modulate CTL epitope processing. J Clin Invest 2007, 117:3563-3575.
29. Mentzer S.J., Guyre P.M., Burakoff S.J., Faller D.V. Spontaneous aggregation as a mechanism for human monocyte purification. Cell Immunol 1986, 101:312-319.
30. Jobe O., Peachman K.K., Matyas G.R., Asher L.V., Alving C.R., Rao M. An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages. Virology 2012, 430:110-119.
31. Steers N.J., Peachman K.K., McClain S.R., Alving C.R., Rao M. Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation. J Virol 2009, 83:7049-7061.
32. Kan-Mitchell J., Bisikirska B., Wong-Staal F., Schaubert K.L., Bajcz M., Bereta M. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope. J Immunol 2004, 172:5249-5261.
33. Solache A., Morgan C.L., Dodi A.I., Morte C., Scott I., Baboonian C., et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 1999, 163:5512-5518.
34. Schaubert K.L., Price D.A., Frahm N., Li J., Ng H.L., Joseph A., et al. Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p 2419-27 epitope. J Immunol 2007, 178:7756-7766.
35. Terajima M., Cruz J., Raines G., Kilpatrick E.D., Kennedy J.S., Rothman A.L., et al. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003, 197:927-932.
36. Steers N.J., Ratto-Kim S., de Souza M.S., Currier J.R., Kim J.H., Michael N.L., et al. HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses. PLoS One 2012, 7:e42579.
37. Liepe J., Mishto M., Textoris-Taube K., Janek K., Keller C., Henklein P., et al. The 20S proteasome splicing activity discovered by SpliceMet. PLoS Comp Biol 2010, 6:e1000830.
38. Stranzl T., Larsen M.V., Lundegaard C., Nielsen M. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 2010, 62:357-368.
39. Draenert R., Le Gall S., Pfafferott K.J., Leslie A.J., Chetty P., Brander C., et al. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 2004, 199:905-915.
40. Ranasinghe S.R., Kramer H.B., Wright C., Kessler B.M., di Gleria K., Zhang Y., et al. The antiviral efficacy of HIV-specific CD8(+) T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PLoS Pathog 2011, 7:e1001341.
41. Seifert U., Liermann H., Racanelli V., Halenius A., Wiese M., Wedemeyer H., et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004, 114:250-259.
42. Ndhlovu Z.M., Piechocka-Trocha A., Vine S., McMullen A., Koofhethile K.C., Goulder P.J., et al. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol 2011, 186:6914-6924.
43. Corey L., McElrath M.J. HIV vaccines: mosaic approach to virus diversity. Nat Med 2010, 16:268-270.
44. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
45. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
46. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001, 19:4652-4660.
47. Wilson C.C., McKinney D., Anders M., MaWhinney S., Forster J., Crimi C., et al. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 2003, 171:5611-5623.
48. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26:215-223.